Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance

被引:11
|
作者
Marra, Giancarlo [1 ,2 ,3 ,4 ]
Soeterik, Timo [5 ]
Oreggia, Davide [1 ,2 ]
Tourinho-Barbosa, Rafael [1 ,2 ]
Moschini, Marco [1 ,2 ]
Filippini, Claudia [3 ,4 ]
van Melick, Harm H. E. [5 ]
van den Bergh, Roderick C. N. [5 ]
Gontero, Paolo [3 ,4 ]
Cathala, Nathalie [1 ,2 ]
Macek, Petr [1 ,2 ]
Sanchez-Salas, Rafael [1 ,2 ]
Cathelineau, Xavier [1 ,2 ]
机构
[1] Inst Mutualiste Montsouris, Dept Urol, Paris, France
[2] Univ Paris 05, Paris, France
[3] Univ Turin, Dept Surg Sci, Turin, Italy
[4] Citta Salute & Sci, Turin, Italy
[5] St Antonius Hosp, Dept Urol, Utrecht, Netherlands
来源
EUROPEAN UROLOGY FOCUS | 2022年 / 8卷 / 03期
关键词
Prostate cancer; Localized disease; Active surveillance; Focal therapy; Cryotherapy; FOLLOW-UP; THERAPY; COMPLICATIONS; PRIAS;
D O I
10.1016/j.euf.2021.04.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: To date, only one trial compared focal therapy and active surveillance (AS) for low-risk prostate cancer (PCa). In addition, long-term outcomes of focal cryotherapy (FC) are lacking. Objective: Our aim was to evaluate long-term outcomes of FC and compare them with AS.Design, setting, and participants: We included two prospective series of 121 (FC) and 459 (AS) consecutive patients (2008-2018) for low-to intermediate-risk PCa.Outcome measurements and statistical analysis: Study outcomes were radical therapy- free or androgen deprivation therapy (ADT)-free, any treatment-free, metastasis-free, and overall survival. A matched pair analysis was performed using seven covariates. Results and limitations: The median FC follow-up was 85 mo (interquartile range 58- 104); 92 (76%) men had International Society of Urological Pathology (ISUP) grade 1. Among matched variables, no significant differences were present except for cT stage and year of entry (both p < 0.01). Ten-year radical therapy-free or ADT-free, any treatment-free, metastasis-free, and overall survival were 51%, 40.2%, 93.9%, and 97%, respectively for FC. No differences were noted with AS (all p > 0.05), with the exception of time to radical therapy, time to radical therapy and ADT, and time to any treatment, all being shorter for AS (all p < 0.01). Freedom from radical treatment or ADT was higher for FC (AS 10 yr 39.3%; p = 0.04). Complications were relatively rare (26.5%) and mainly of low grade (Clavien >2, n = 3); three men developed incontinence (p = 0.0814), while both International Index of Erectile Function 5 and International Prostate Symptom Score scores increased (p = 0.0287 and p = 0.0165, respectively). Limitations include absence of randomization.Conclusions: At an early long-term follow-up, FC in the context of mainly low-risk PCa is safe and increases time to radical therapy but does not provide meaningful oncological advantages compared with AS.Patient summary: We compared focal cryotherapy with active surveillance mainly for low-risk prostate cancer. Focal cryotherapy, despite having fewer complications, did not yield meaningful advantages over active surveillance at 10 yr. Active surveillance should be preferred to focal cryotherapy for these patients.(c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:701 / 709
页数:9
相关论文
共 50 条
  • [1] FOCAL CRYOTHERAPY FOR LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: LONG TERM RESULTS AND MATCHED PAIR COMPARISON WITH ACTIVE SURVEILLANCE
    Marra, Giancarlo
    Soeterik, Timo
    Oreggia, Davide
    Pasquali, Caio
    Tourinho-Barbosa, Rafael
    Moschini, Marco
    Filippini, Claudia
    van Melick, Harm H. E.
    van den Bergh, Roderick C. N.
    Gontero, Paolo
    Cathala, Nathalie
    Macek, Petr
    Sanchez-Salas, Rafael
    Cathelineau, Xavier
    JOURNAL OF UROLOGY, 2021, 206 : E817 - E817
  • [2] Active surveillance in low- and intermediate-risk prostate cancer
    Cerbone, Linda
    Regine, Giovanni
    Calabro, Fabio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 582 - 583
  • [3] Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
    Valentin H. Meissner
    Mira Woll
    Donna P. Ankerst
    Stefan Schiele
    Jürgen E. Gschwend
    Kathleen Herkommer
    World Journal of Urology, 2021, 39 : 3763 - 3770
  • [4] Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
    Meissner, Valentin H.
    Woll, Mira
    Ankerst, Donna P.
    Schiele, Stefan
    Gschwend, Juergen E.
    Herkommer, Kathleen
    WORLD JOURNAL OF UROLOGY, 2021, 39 (10) : 3763 - 3770
  • [5] Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
    Henk van der Poel
    Laurence Klotz
    Gerald Andriole
    Abdel-Rahmène Azzouzi
    Anders Bjartell
    Olivier Cussenot
    Freddy Hamdy
    Markus Graefen
    Paolo Palma
    Arturo Rodriguez Rivera
    Christian G. Stief
    World Journal of Urology, 2015, 33 : 907 - 916
  • [6] Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
    van der Poel, Henk
    Klotz, Laurence
    Andriole, Gerald
    Azzouzi, Abdel-Rahmene
    Bjartell, Anders
    Cussenot, Olivier
    Hamdy, Freddy
    Graefen, Markus
    Palma, Paolo
    Rodriguez Rivera, Arturo
    Stief, Christian G.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 907 - 916
  • [7] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Cyll, Karolina
    Loffeler, Sven
    Carlsen, Birgitte
    Skogstad, Karin
    Plathan, May Lisbeth
    Landquist, Martin
    Haug, Erik Skaaheim
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [8] Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
    Courtney, P. Travis
    Deka, Rishi
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Salans, Mia A.
    Nelson, Tyler J.
    Kumar, Abhishek
    Luterstein, Elaine
    Yip, Anthony T.
    Nalawade, Vinit
    Parsons, J. Kellogg
    Kader, A. Karim
    Stewart, Tyler F.
    Rose, Brent S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 151 - +
  • [9] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Karolina Cyll
    Sven Löffeler
    Birgitte Carlsen
    Karin Skogstad
    May Lisbeth Plathan
    Martin Landquist
    Erik Skaaheim Haug
    Scientific Reports, 12
  • [10] Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance
    Whalen, Michael J.
    Pak, Jamie S.
    Lascano, Danny
    Ahlborn, David
    Matulay, Justin T.
    McKiernan, James M.
    Benson, Mitchell C.
    Wenske, Sven
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E425 - E435